Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy TRACON Pharmaceuticals stock | $3.71

Learn how to easily invest in TRACON Pharmaceuticals stock.

TRACON Pharmaceuticals Inc is a biotechnology business based in the US. TRACON Pharmaceuticals shares (TCON) are listed on the NASDAQ and all prices are listed in US Dollars. TRACON Pharmaceuticals employs 18 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in TRACON Pharmaceuticals

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – TCON – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

TRACON Pharmaceuticals stock price (NASDAQ: TCON)

Use our graph to track the performance of TCON stocks over time.

TRACON Pharmaceuticals shares at a glance

Information last updated 2021-10-17.
Latest market close$3.71
52-week range$3.21 - $12.20
50-day moving average $3.90
200-day moving average $5.45
Wall St. target price$11.86
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-1.61

Buy TRACON Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
$20 per year
Financial advice powered by relationships, not commissions.
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy TRACON Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

TRACON Pharmaceuticals price performance over time

Historical closes compared with the close of $3.71 from 2021-10-22

1 week (2021-10-15) -1.85%
1 month (2021-09-24) -13.11%
3 months (2021-07-23) -2.37%
6 months (2021-04-23) -50.73%
1 year (2020-10-23) -24.90%
2 years (2019-10-24) 1,116.39%
3 years (2018-10-24) 162.97%
5 years (2016-10-24) 5.95

TRACON Pharmaceuticals financials

Revenue TTM $346,000
Gross profit TTM $-8,198,000
Return on assets TTM -64.27%
Return on equity TTM -299.05%
Profit margin 0%
Book value $0.77
Market capitalisation $73.4 million

TTM: trailing 12 months

Shorting TRACON Pharmaceuticals shares

There are currently 309,702 TRACON Pharmaceuticals shares held short by investors – that's known as TRACON Pharmaceuticals's "short interest". This figure is 2.4% up from 302,528 last month.

There are a few different ways that this level of interest in shorting TRACON Pharmaceuticals shares can be evaluated.

TRACON Pharmaceuticals's "short interest ratio" (SIR)

TRACON Pharmaceuticals's "short interest ratio" (SIR) is the quantity of TRACON Pharmaceuticals shares currently shorted divided by the average quantity of TRACON Pharmaceuticals shares traded daily (recently around 165616.04278075). TRACON Pharmaceuticals's SIR currently stands at 1.87. In other words for every 100,000 TRACON Pharmaceuticals shares traded daily on the market, roughly 1870 shares are currently held short.

However TRACON Pharmaceuticals's short interest can also be evaluated against the total number of TRACON Pharmaceuticals shares, or, against the total number of tradable TRACON Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case TRACON Pharmaceuticals's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 TRACON Pharmaceuticals shares in existence, roughly 20 shares are currently held short) or 0.0222% of the tradable shares (for every 100,000 tradable TRACON Pharmaceuticals shares, roughly 22 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against TRACON Pharmaceuticals.

Find out more about how you can short TRACON Pharmaceuticals stock.

TRACON Pharmaceuticals share dividends

We're not expecting TRACON Pharmaceuticals to pay a dividend over the next 12 months.

Have TRACON Pharmaceuticals's shares ever split?

TRACON Pharmaceuticals's shares were split on a 1:10 basis on 7 November 2019. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your TRACON Pharmaceuticals shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for TRACON Pharmaceuticals shares which in turn could have impacted TRACON Pharmaceuticals's share price.

TRACON Pharmaceuticals share price volatility

Over the last 12 months, TRACON Pharmaceuticals's shares have ranged in value from as little as $3.21 up to $12.2. A popular way to gauge a stock's volatility is its "beta".

TCON.US volatility(beta: 1.81)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while TRACON Pharmaceuticals's is 1.8079. This would suggest that TRACON Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

TRACON Pharmaceuticals overview

TRACON Pharmaceuticals, Inc. , a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer and age-related macular degeneration and fibrotic diseases in the United States. Its lead clinical stage product include envafolimab (KN035), an investigational PD-L1 single-domain antibody for the treatment of soft tissue sarcoma. The company's clinical stage products also include TRC102, which is a small molecule that is in Phase II clinical trial for the treatment of mesothelioma, Phase I clinical trial to treat solid tumors, Phase I to treat solid tumors and lymphomas, and Phase I trial to treat lung cancer; TRC253, a small molecule, which is in Phase II clinical trial for the treatment of metastatic castration-resistant prostate cancer; and TJ004309, a CD73 antibody that is in Phase I clinical development for the treatment of solid tumors. It has collaboration and license agreements with 3D Medicines Co. , Ltd. and Jiangsu Alphamab Biopharmaceuticals Co.

Frequently asked questions

What percentage of TRACON Pharmaceuticals is owned by insiders or institutions?
Currently 1.34% of TRACON Pharmaceuticals shares are held by insiders and 47.831% by institutions.
How many people work for TRACON Pharmaceuticals?
Latest data suggests 18 work at TRACON Pharmaceuticals.
When does the fiscal year end for TRACON Pharmaceuticals?
TRACON Pharmaceuticals's fiscal year ends in December.
Where is TRACON Pharmaceuticals based?
TRACON Pharmaceuticals's address is: 4350 La Jolla Village Drive, San Diego, CA, United States, 92122
What is TRACON Pharmaceuticals's ISIN number?
TRACON Pharmaceuticals's international securities identification number is: US89237H2094
What is TRACON Pharmaceuticals's CUSIP number?
TRACON Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 89237H100

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site